Pulmonary Drug Delivery Market Size to Surpass USD 72.88 Billion by 2030, Demand, Global Trends, Challenges and Competitive Outlook

PRESS RELEASE
Published May 25, 2023

Data Bridge Market Research Published Latest Global Pulmonary Drug Delivery Market Study by in-depth analysis about current scenario, the Market size, demand, growth pattern, trends, and forecast. This report on the study considers important factors such as an analysis of the market, a definition of the market, market segmentation, significant trends in the industry, an examination of the competitive landscape, and research methodology.

The primary goal of the drug delivery route, known as pulmonary drug delivery, is to deposit inhaled pharmacological agents in lower airways with devices that assist with inhaling drug formulations through the mouth. They are extensively used in various end-user industries, including hospitals, clinics, and home care settings. Numerous devices are used for respiratory delivery, including nebulizers, metered-dose inhalers, and dry powder inhalers. Inhaled beta-agonists, corticosteroids, and anticholinergic medications are delivered through the lungs to treat asthma and chronic obstructive pulmonary disease (COPD). The pulmonary administration route has several advantages. The medication is administered right to the disease site to treat respiratory diseases.

Data Bridge Market Research analyses that the pulmonary drug delivery market, valued at USD 47.85 billion in 2022, will reach USD 72.88 billion by 2030, growing at a CAGR of 5.4% during the forecast period of 2023 to 2030.  In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Download PDF Sample Global Pulmonary Drug Delivery Market Report (Including Graphs, Charts, and List of Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pulmonary-drug-delivery-market

Directing the drug to the intended site is referred to as “targeted drug delivery.” A targeted drug delivery system called pulmonary drug delivery requires the drug moiety toward the lower respiratory tract. A device used to administer medications to the body via the pulmonary route is called a pulmonary drug delivery system. The inhalation route offers a superior alternative to oral administration for treating asthma and chronic obstructive pulmonary disease. Instantaneous action from pulmonary drug delivery relieves acute bronchitis and asthmatic attacks. For pulmonary drug delivery, aerosols are specially made-devices.

Drivers

  • Rising prevalence of severe respiratory surges the demand

The rising prevalence of severe respiratory diseases like cystic fibrosis and chronic obstructive pulmonary disease is driving the growth of the pulmonary drug delivery market. Additionally, the growing demand for minimally invasive and effective treatments and the rising trend of pulmonary drug delivery due to features of a large porous area, thin absorbent mucosal membrane, and efficient blood supply will boost the market growth. Additionally, the rising smoking prevalence can impact respiratory, further accelerating the market’s overall growth.

  •  The prevalence of pulmonary diseases drives the market

An increase in air pollution in the prevalence of pulmonary diseases such as asthma and chronic obstructive pulmonary disease, has showcase growing number of hospitals and diagnostic facilities, a surge in funding from private and public organizations for the treatment of pulmonary diseases, and an increase in public awareness of pulmonary health are the main factors driving the global market for pulmonary drug delivery systems. The World Health Organization reports that 9 out of 10 people breathe air that contains high levels of pollutants, and estimates indicate that in 2018, ambient (outdoor) and household air pollution will be responsible for an alarming 7 million annual deaths.

Recent Developments

  • In 2022, Subintro’s acquisition by RIGImmune gave it access to cutting-edge topical delivery systems. With this agreement, the biotech is better positioned to advance the creation of cutting-edge RNA therapies and vaccine adjuvants for local mucosal delivery.
  • In 2022, Orbital Dry Powder Inhaler (DPI) worldwide license was acquired by Aptar Pharma. This acquisition will enable Aptar Pharma to meet the rising demand for easy and secure high-dose lung treatment administration.
  • In 2020, The U.S. Food and Drug Administration (FDA) received a New Drug Application (NDA) for UPTRAVI (selexipag) as an intravenous (IV) injection to treat pulmonary arterial hypertension from Johnson & Johnson’s Janssen Pharmaceutical Companies.
  • In 2020, The Japanese Ministry of Health, Labour, and Welfare (MHLW) simultaneously approved new treatment options for Japanese patients, according to news released by Novartis Pharma K.K. (“Novartis Pharma”). For advanced and recurrent untreatable non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation, TabrectaTM (capmatinib, formerly INC280) is an oral MET inhibitor.

Some of the major players operating in the pulmonary drug delivery market are:

  • F. Hoffmann-La Roche Ltd (Switzerland)
  • MannKind Corporation (U.S.)
  • OMRON Healthcare, Inc. (Japan)
  • Mylan N.V (U.S.)
  • 3M (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • Merck & Co., Inc., (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sunovion Pharmaceuticals Inc. (U.S.)
  • PARI GmbH (Germany)
  • Jabil Inc. (U.S.)
  • AstraZeneca (U.K.)
  • Boehringer Ingelheim International GmbH. (Germany)
  • GSK plc. (U.K.)
  • Novartis AG (Switzerland)
  • Aerogen Pharma (Ireland)
  • Briggs Healthcare (U.S.)
  • HAAG-STREIT GROUP (Switzerland)
  • Janssen Global Services, LLC (U.S.)
  • AptarGroup, Inc. (U.S.)

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@  https://www.databridgemarketresearch.com/reports/global-pulmonary-drug-delivery-market

Key Pointers Covered in the Pulmonary Drug Delivery Market Industry Trends and Forecast to 2029

  • Market Size
  • Market New Sales Volumes
  • Market Replacement Sales Volumes
  • Market Installed Base
  • Market By Brands
  • Market Procedure Volumes
  • Market Product Price Analysis
  • Market Healthcare Outcomes
  • Market Cost of Care Analysis
  • Market Regulatory Framework and Changes
  • Market Prices and Reimbursement Analysis
  • Market Shares in Different Regions
  • Recent Developments for Market Competitors
  • Market Upcoming Applications

Global Pulmonary Drug Delivery Market Scope

Formulations

  • Type
  • Suspension aerosol
  • Solution Aerosal
  • Dry power formulation
  • Device type
  • Dry Powder Inhalers
  • Single-Dose Inhalers
  • Multi-Dose Inhaler
  • Metered Dose Inhalers
  • Manually-Actuated Pressurized Inhaler
  • Breath-Actuated Pressurized Inhaler
  • Nebulizers
  • Jet Nebulizers
  • Soft Mist Nebulizers
  • Ultra Wave Nebulizers
  • Mesh
  • Vibrating
  • Static
  • Pneumatic
  • Vented
  • Breath Actuated
  • Accessories

Canister Type

  • Plain Canister
  • Coated Canister

Application

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Cystic Fibrosis
  • Allergic Rhinitis
  • Other

End-User

  • Hospitals and Clinics
  • Home Care Settings

Browse the complete table of contents at – https://www.databridgemarketresearch.com/toc/?dbmr=global-pulmonary-drug-delivery-market

Top DBMR Healthcare Reports:        

Injectable Drug Delivery Market – Industry Trends and Forecast to 2029

https://www.databridgemarketresearch.com/reports/north-america-injectable-drug-delivery-market

https://www.databridgemarketresearch.com/reports/europe-injectable-drug-delivery-market

https://www.databridgemarketresearch.com/reports/europe-injectable-drug-delivery-market

Drug Delivery Devices Market – Industry Trends and Forecast to 2029

Topical Drug Delivery Market – Industry Trends and Forecast to 2029

https://www.databridgemarketresearch.com/reports/north-america-drug-delivery-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com

CDN Newswire